Cargando…

Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study

BACKGROUND: Data are lacking from general population studies on how to define changes in lung function after bronchodilation. This study aimed to analyze different measures of bronchodilator response of forced expiratory volume in 1 second (FEV(1)), forced vital capacity (FVC) and slow vital capacit...

Descripción completa

Detalles Bibliográficos
Autores principales: Torén, K, Bake, B, Olin, A-C, Engström, G, Blomberg, A, Vikgren, J, Hedner, J, Brandberg, J, Persson, HL, Sköld, CM, Rosengren, A, Bergström, G, Janson, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367735/
https://www.ncbi.nlm.nih.gov/pubmed/28356729
http://dx.doi.org/10.2147/COPD.S127336
_version_ 1782517821468573696
author Torén, K
Bake, B
Olin, A-C
Engström, G
Blomberg, A
Vikgren, J
Hedner, J
Brandberg, J
Persson, HL
Sköld, CM
Rosengren, A
Bergström, G
Janson, C
author_facet Torén, K
Bake, B
Olin, A-C
Engström, G
Blomberg, A
Vikgren, J
Hedner, J
Brandberg, J
Persson, HL
Sköld, CM
Rosengren, A
Bergström, G
Janson, C
author_sort Torén, K
collection PubMed
description BACKGROUND: Data are lacking from general population studies on how to define changes in lung function after bronchodilation. This study aimed to analyze different measures of bronchodilator response of forced expiratory volume in 1 second (FEV(1)), forced vital capacity (FVC) and slow vital capacity (SVC). MATERIALS AND METHODS: Data were derived from the Swedish Cardiopulmonary Bioimage Study (SCAPIS) Pilot study. This analysis comprised 1,050 participants aged 50–64 years from the general population. Participants were investigated using a questionnaire, and FEV(1), FVC and SVC were recorded before and 15 minutes after inhalation of 400 µg of salbutamol. A bronchodilator response was defined as the relative change from baseline value expressed as the difference in units of percent predicted normal. Predictors of bronchodilator responses were assessed using multiple linear regression models. Airway obstruction was defined as FEV(1)/FVC ratio below lower limit of normal (LLN) before bronchodilation, and COPD was defined as an FEV(1)/FVC ratio below LLN after bronchodilation. Physician-diagnosed asthma was defined as an affirmative answer to “Have you ever had asthma diagnosed by a physician?”. Asymptomatic never-smokers were defined as those not reporting physician-diagnosed asthma, physician-diagnosed COPD or emphysema, current wheeze or chronic bronchitis and being a lifelong never-smoker. RESULTS: Among all subjects, the greatest bronchodilator responses (FEV(1), FVC and SVC) were found in subjects with asthma or COPD. The upper 95th percentile of bronchodilator responses in asymptomatic never-smokers was 8.7% for FEV(1), 4.2% for FVC and 5.0% for SVC. The bronchodilator responses were similar between men and women. In a multiple linear regression model comprising all asymptomatic never-smokers, the bronchodilator response of FEV(1) was significantly associated with airway obstruction and height. CONCLUSION: When the bronchodilator response in asymptomatic never-smokers is reported as the difference in units of predicted normal, significant reversibility of FEV(1), FVC and SVC to bronchodilators is ~9%, 4% and 5%, respectively.
format Online
Article
Text
id pubmed-5367735
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53677352017-03-29 Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study Torén, K Bake, B Olin, A-C Engström, G Blomberg, A Vikgren, J Hedner, J Brandberg, J Persson, HL Sköld, CM Rosengren, A Bergström, G Janson, C Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Data are lacking from general population studies on how to define changes in lung function after bronchodilation. This study aimed to analyze different measures of bronchodilator response of forced expiratory volume in 1 second (FEV(1)), forced vital capacity (FVC) and slow vital capacity (SVC). MATERIALS AND METHODS: Data were derived from the Swedish Cardiopulmonary Bioimage Study (SCAPIS) Pilot study. This analysis comprised 1,050 participants aged 50–64 years from the general population. Participants were investigated using a questionnaire, and FEV(1), FVC and SVC were recorded before and 15 minutes after inhalation of 400 µg of salbutamol. A bronchodilator response was defined as the relative change from baseline value expressed as the difference in units of percent predicted normal. Predictors of bronchodilator responses were assessed using multiple linear regression models. Airway obstruction was defined as FEV(1)/FVC ratio below lower limit of normal (LLN) before bronchodilation, and COPD was defined as an FEV(1)/FVC ratio below LLN after bronchodilation. Physician-diagnosed asthma was defined as an affirmative answer to “Have you ever had asthma diagnosed by a physician?”. Asymptomatic never-smokers were defined as those not reporting physician-diagnosed asthma, physician-diagnosed COPD or emphysema, current wheeze or chronic bronchitis and being a lifelong never-smoker. RESULTS: Among all subjects, the greatest bronchodilator responses (FEV(1), FVC and SVC) were found in subjects with asthma or COPD. The upper 95th percentile of bronchodilator responses in asymptomatic never-smokers was 8.7% for FEV(1), 4.2% for FVC and 5.0% for SVC. The bronchodilator responses were similar between men and women. In a multiple linear regression model comprising all asymptomatic never-smokers, the bronchodilator response of FEV(1) was significantly associated with airway obstruction and height. CONCLUSION: When the bronchodilator response in asymptomatic never-smokers is reported as the difference in units of predicted normal, significant reversibility of FEV(1), FVC and SVC to bronchodilators is ~9%, 4% and 5%, respectively. Dove Medical Press 2017-03-22 /pmc/articles/PMC5367735/ /pubmed/28356729 http://dx.doi.org/10.2147/COPD.S127336 Text en © 2017 Torén et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Torén, K
Bake, B
Olin, A-C
Engström, G
Blomberg, A
Vikgren, J
Hedner, J
Brandberg, J
Persson, HL
Sköld, CM
Rosengren, A
Bergström, G
Janson, C
Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study
title Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study
title_full Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study
title_fullStr Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study
title_full_unstemmed Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study
title_short Measures of bronchodilator response of FEV(1), FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS Pilot Study
title_sort measures of bronchodilator response of fev(1), fvc and svc in a swedish general population sample aged 50–64 years, the scapis pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367735/
https://www.ncbi.nlm.nih.gov/pubmed/28356729
http://dx.doi.org/10.2147/COPD.S127336
work_keys_str_mv AT torenk measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT bakeb measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT olinac measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT engstromg measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT blomberga measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT vikgrenj measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT hednerj measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT brandbergj measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT perssonhl measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT skoldcm measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT rosengrena measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT bergstromg measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy
AT jansonc measuresofbronchodilatorresponseoffev1fvcandsvcinaswedishgeneralpopulationsampleaged5064yearsthescapispilotstudy